Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP).
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
26
02
2023
accepted:
23
08
2023
revised:
12
08
2023
medline:
4
12
2023
pubmed:
7
9
2023
entrez:
6
9
2023
Statut:
ppublish
Résumé
The COVID-19 pandemic has had a significant impact on medical practices, including the delivery of allogeneic hematopoietic cell transplantation (HCT). In response, transplant centers have made changes to their procedures, including an increased use of cryopreservation for allogeneic haematopoietic progenitor cell (HPC) grafts. The use of cryopreserved grafts for allogeneic HCT has been reviewed and analysed in terms of potential benefits and drawbacks based on existing data on impact on cell subsets, hematological recovery, and clinical outcomes of approximately 2000 patients from different studies. A survey of European Society for Blood and Marrow Transplantation centers was also conducted to assess changes in practice during the pandemic and any unnecessary burdens on HPC donors. Before the pandemic, only 7.4% of transplant centers were routinely cryopreserving HPC products, but this percentage increased to 90% during the pandemic. The results of this review and survey suggest that cryopreservation of HPC grafts is a viable option for allogeneic HCT in certain situations, but further research is needed to determine long-term effects and ethical discussions are required to balance the needs of donors and patients when using frozen allografts.
Identifiants
pubmed: 37673982
doi: 10.1038/s41409-023-02099-w
pii: 10.1038/s41409-023-02099-w
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1348-1356Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Worel N, Shaw BE, Aljurf M, Koh M, Seber A, Weisdorf D, et al. Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation. Transpl Cell Ther. 2021;27:270. https://doi.org/10.1016/j.jtct.2020.11.019 .
doi: 10.1016/j.jtct.2020.11.019
Faulkner J, O’Brien WJ, McGrane B, Wadsworth D, Batten J, Askew CD, et al. Physical activity, mental health and well-being of adults during initial COVID-19 containment strategies: A multi-country cross-sectional analysis. J Sci Med Sport. 2021;24:320–6. https://doi.org/10.1016/j.jsams.2020.11.016 .
doi: 10.1016/j.jsams.2020.11.016
pubmed: 33341382
Al Hamed R, Bazarbachi AH, Malard F, Harousseau JL, Mohty M. Current status of autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2019;9:44. https://doi.org/10.1038/s41408-019-0205-9 .
doi: 10.1038/s41408-019-0205-9
pubmed: 30962422
pmcid: 6453900
Mohty M, Hubel K, Kroger N, Aljurf M, Apperley J, Basak GW, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:865–72. https://doi.org/10.1038/bmt.2014.39 .
doi: 10.1038/bmt.2014.39
pubmed: 24686988
Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, et al. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transpl. 2003;9:643–8. https://doi.org/10.1016/s1083-8791(03)00232-5 .
doi: 10.1016/s1083-8791(03)00232-5
Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, et al. High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncotarget. 2016;7:27255–66. https://doi.org/10.18632/oncotarget.8463 .
doi: 10.18632/oncotarget.8463
pubmed: 27036034
pmcid: 5053647
Arcuri LJ, Nabhan SK, Cunha R, Nichele S, Ribeiro AAF, Fernandes JF, et al. Impact of CD34 Cell Dose and Conditioning Regimen on Outcomes after Haploidentical Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Relapsed/Refractory Severe Aplastic Anemia. Biol Blood Marrow Transpl. 2020;26:2311–7. https://doi.org/10.1016/j.bbmt.2020.09.007 .
doi: 10.1016/j.bbmt.2020.09.007
Czerw T, Iacobelli S, Malpassuti V, Koster L, Kroger N, Robin M, et al. Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. Bone marrow Transplant. 2022;57:261–70. https://doi.org/10.1038/s41409-021-01540-2 .
doi: 10.1038/s41409-021-01540-2
pubmed: 34853433
Politikos I, Davis E, Nhaissi M, Wagner JE, Brunstein CG, Cohen S, et al. Guidelines for Cord Blood Unit Selection. Biol Blood Marrow Transpl. 2020;26:2190–6. https://doi.org/10.1016/j.bbmt.2020.07.030 .
doi: 10.1016/j.bbmt.2020.07.030
Ruggeri A. Optimizing cord blood selection. Hematol Am Soc Hematol Educ Program. 2019;2019:522–31. https://doi.org/10.1182/hematology.2019000056 .
doi: 10.1182/hematology.2019000056
Blazar BR, Hill GR, Murphy WJ. Dissecting the biology of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. Nat Rev Clin Oncol. 2020;17:475–92. https://doi.org/10.1038/s41571-020-0356-4 .
doi: 10.1038/s41571-020-0356-4
pubmed: 32313224
pmcid: 7901860
Kuball J, Boelens JJ. Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization. In: th, Carreras E, Dufour C, Mohty M, Kroger N (eds). The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies: Cham (CH), 2019, pp 69–74.
Cox JH, Ferrari G, Kalams SA, Lopaczynski W, Oden N, D’Souza MP, et al. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res Hum Retroviruses. 2005;21:68–81. https://doi.org/10.1089/aid.2005.21.68 .
doi: 10.1089/aid.2005.21.68
pubmed: 15665646
Ramachandran H, Laux J, Moldovan I, Caspell R, Lehmann PV, Subbramanian RA. Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies. Cells. 2012;1:313–24. https://doi.org/10.3390/cells1030313 .
doi: 10.3390/cells1030313
pubmed: 24710478
pmcid: 3901099
Li Y, Mateu E, Diaz I. Impact of Cryopreservation on Viability, Phenotype, and Functionality of Porcine PBMC. Front Immunol. 2021;12:765667. https://doi.org/10.3389/fimmu.2021.765667 .
doi: 10.3389/fimmu.2021.765667
pubmed: 34912338
pmcid: 8666977
Panch SR, Srivastava SK, Elavia N, McManus A, Liu S, Jin P, et al. Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics. Mol Ther. 2019;27:1275–85. https://doi.org/10.1016/j.ymthe.2019.05.015 .
doi: 10.1016/j.ymthe.2019.05.015
pubmed: 31178392
pmcid: 6612799
Pi CH, Hornberger K, Dosa P, Hubel A. Understanding the freezing responses of T cells and other subsets of human peripheral blood mononuclear cells using DSMO-free cryoprotectants. Cytotherapy. 2020;22:291–300. https://doi.org/10.1016/j.jcyt.2020.01.013 .
doi: 10.1016/j.jcyt.2020.01.013
pubmed: 32220549
pmcid: 7682753
Xu H, Cao W, Huang L, Xiao M, Cao Y, Zhao L, et al. Effects of cryopreservation on chimeric antigen receptor T cell functions. Cryobiology. 2018;83:40–47. https://doi.org/10.1016/j.cryobiol.2018.06.007 .
doi: 10.1016/j.cryobiol.2018.06.007
pubmed: 29908946
Costantini A, Mancini S, Giuliodoro S, Butini L, Regnery CM, Silvestri G, et al. Effects of cryopreservation on lymphocyte immunophenotype and function. J Immunol Methods. 2003;278:145–55. https://doi.org/10.1016/s0022-1759(03)00202-3 .
doi: 10.1016/s0022-1759(03)00202-3
pubmed: 12957403
Luo Y, Wang P, Liu H, Zhu Z, Li C, Gao Y. The state of T cells before cryopreservation: Effects on post-thaw proliferation and function. Cryobiology. 2017;79:65–70. https://doi.org/10.1016/j.cryobiol.2017.08.008 .
doi: 10.1016/j.cryobiol.2017.08.008
pubmed: 28863950
Capelle CM, Cire S, Ammerlaan W, Konstantinou M, Balling R, Betsou F, et al. Standard PBMC cryopreservation selectively decreases detection of nine clinically-relevant T-cell markers. ImmunoHorizons. 2021. https://doi.org/10.1101/2021.05.18.443634 .
Svalgaard JD, Talkhoncheh MS, Haastrup EK, Munthe-Fog L, Clausen C, Hansen MB, et al. Pentaisomaltose, an Alternative to DMSO. Engraftment of Cryopreserved Human CD34(+) Cells in Immunodeficient NSG Mice. Cell Transpl. 2018;27:1407–12. https://doi.org/10.1177/0963689718786226 .
doi: 10.1177/0963689718786226
Duchez P, Chevaleyre J, Brunet de la Grange P, Vlaski M, Boiron JM, Wouters G, et al. Cryopreservation of hematopoietic stem and progenitor cells amplified ex vivo from cord blood CD34+ cells. Transfusion. 2013;53:2012–9. https://doi.org/10.1111/trf.12015 .
doi: 10.1111/trf.12015
pubmed: 23227804
Sartor M, Antonenas V, Garvin F, Webb M, Bradstock KF. Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transpl. 2005;36:199–204. https://doi.org/10.1038/sj.bmt.1705009 .
doi: 10.1038/sj.bmt.1705009
Berens C, Heine A, Müller J, Held SAE, Mayer K, Brossart P, et al. Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. Cytotherapy. 2016;18:1325–31. https://doi.org/10.1016/j.jcyt.2016.06.014 .
doi: 10.1016/j.jcyt.2016.06.014
pubmed: 27491794
Kaushal R, Jahan S, McGregor C, Pineault N. Dimethyl sulfoxide-free cryopreservation solutions for hematopoietic stem cell grafts. Cytotherapy. 2022;24:272–81. https://doi.org/10.1016/j.jcyt.2021.09.002 .
doi: 10.1016/j.jcyt.2021.09.002
pubmed: 34654640
Pollock K, Yu G, Moller-Trane R, Koran M, Dosa PI, McKenna DH, et al. Combinations of Osmolytes, Including Monosaccharides, Disaccharides, and Sugar Alcohols Act in Concert During Cryopreservation to Improve Mesenchymal Stromal Cell Survival. Tissue Eng Part C Methods. 2016;22:999–1008. https://doi.org/10.1089/ten.TEC.2016.0284 .
doi: 10.1089/ten.TEC.2016.0284
pubmed: 27758133
pmcid: 5125256
Matsumura K, Hyon SH. Polyampholytes as low toxic efficient cryoprotective agents with antifreeze protein properties. Biomaterials. 2009;30:4842–9. https://doi.org/10.1016/j.biomaterials.2009.05.025 .
doi: 10.1016/j.biomaterials.2009.05.025
pubmed: 19515417
Ota A, Matsumura K, Lee JJ, Sumi S, Hyon SH. StemCell Keep Is Effective for Cryopreservation of Human Embryonic Stem Cells by Vitrification. Cell Transpl. 2017;26:773–87. https://doi.org/10.3727/096368916X692654 .
doi: 10.3727/096368916X692654
Li R, Hornberger K, Dutton JR, Hubel A. Cryopreservation of Human iPS Cell Aggregates in a DMSO-Free Solution-An Optimization and Comparative Study. Front Bioeng Biotechnol. 2020;8:1. https://doi.org/10.3389/fbioe.2020.00001 .
doi: 10.3389/fbioe.2020.00001
pubmed: 32039188
pmcid: 6987262
Pasley S, Zylberberg C, Matosevic S. Natural killer-92 cells maintain cytotoxic activity after long-term cryopreservation in novel DMSO-free media. Immunol Lett. 2017;192:35–41. https://doi.org/10.1016/j.imlet.2017.09.012 .
doi: 10.1016/j.imlet.2017.09.012
pubmed: 28966059
Lamure S, Paul F, Gagez AL, Delage J, Vincent L, Fegueux N, et al. A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment. J Clin Med. 2020;9. https://doi.org/10.3390/jcm9072204 .
Lasky LC, Van Buren N, Weisdorf DJ, Filipovich A, McGlave P, Kersey JH, et al. Successful allogeneic cryopreserved marrow transplantation. Transfusion. 1989;29:182–4. https://doi.org/10.1046/j.1537-2995.1989.29289146840.x .
doi: 10.1046/j.1537-2995.1989.29289146840.x
pubmed: 2645697
Eckardt JR, Roodman GD, Boldt DH, Clark GM, Alvarez R, Page C, et al. Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT. Bone Marrow Transpl. 1993;11:125–31.
Stockschlader M, Kruger W, tom Dieck A, Horstmann M, Altnoder M, Loliger C. et al. Use of cryopreserved bone marrow in unrelated allogeneic transplantation. Bone Marrow Transpl. 1996;17:197–9.
Stockschlader M, Hassan HT, Krog C, Kruger W, Loliger C, Horstman M, et al. Long-term follow-up of leukaemia patients after related cryopreserved allogeneic bone marrow transplantation. Br J Haematol. 1997;96:382–6. https://doi.org/10.1046/j.1365-2141.1997.d01-2032.x .
doi: 10.1046/j.1365-2141.1997.d01-2032.x
pubmed: 9029030
Parody R, Caballero D, Marquez-Malaver FJ, Vazquez L, Saldana R, Madrigal MD, et al. To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors. Eur J Haematol. 2013;91:448–55. https://doi.org/10.1111/ejh.12140 .
doi: 10.1111/ejh.12140
pubmed: 23710624
Kim DH, Jamal N, Saragosa R, Loach D, Wright J, Gupta V, et al. Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts. Biol Blood Marrow Transpl. 2007;13:1233–43. https://doi.org/10.1016/j.bbmt.2007.07.003 .
doi: 10.1016/j.bbmt.2007.07.003
Alotaibi AS, Prem S, Chen S, Lipton JH, Kim DD, Viswabandya A, et al. Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option. Am J Hematol. 2021;96:179–87. https://doi.org/10.1002/ajh.26033 .
Medd P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival. Bone marrow Transplant. 2013;48:243–8. https://doi.org/10.1038/bmt.2012.118 .
doi: 10.1038/bmt.2012.118
pubmed: 22732701
Dagdas S, Ucar MA, Ceran F, Gunes AK, Falay M, Ozet G. Comparison of allogenic stem cell transplantations performed with frozen or fresh stem cell products with regard to GVHD and mortality. Transfus Apher Sci. 2020;59:102742. https://doi.org/10.1016/j.transci.2020.102742 .
doi: 10.1016/j.transci.2020.102742
pubmed: 32171686
Ghobadi A, Fiala MA, Ramsingh G, Gao F, Abboud CN, Stockerl-Goldstein K, et al. Fresh or Cryopreserved CD34(+)-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2017;23:1072–7. https://doi.org/10.1016/j.bbmt.2017.03.019 .
doi: 10.1016/j.bbmt.2017.03.019
Jacob RP, Flynn J, Devlin SM, Maloy M, Giralt SA, Maslak P, et al. Universal Engraftment after Allogeneic Hematopoietic Cell Transplantation Using Cryopreserved CD34-Selected Grafts. Transpl Cell Ther. 2021;27:697.e691–5. https://doi.org/10.1016/j.jtct.2021.04.026 .
doi: 10.1016/j.jtct.2021.04.026
Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, et al. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transpl. 2020;26:1312–7. https://doi.org/10.1016/j.bbmt.2020.04.001 .
doi: 10.1016/j.bbmt.2020.04.001
Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, et al. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. Transpl Cell Ther. 2021;27:507–16. https://doi.org/10.1016/j.jtct.2021.03.015 .
doi: 10.1016/j.jtct.2021.03.015
Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, et al. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. Biol Blood Marrow Transpl. 2020;26:e161–6. https://doi.org/10.1016/j.bbmt.2020.04.027 .
doi: 10.1016/j.bbmt.2020.04.027
Fadeyi E, Mamo YT, Saha AK, Wilson E, Pomper G. The Viability of Hematopoietic Progenitor Cell Grafts after Cryopreservation Does Not Predict Delayed Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation. Lab Med. 2022;53:509–13. https://doi.org/10.1093/labmed/lmac042 .
doi: 10.1093/labmed/lmac042
pubmed: 35640044
Novitzky-Basso I, Remberger M, Chen C, Pasic I, Lam W, Law A, et al. Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts. Eur J Haematol. 2022;108:61–72. https://doi.org/10.1111/ejh.13714 .
doi: 10.1111/ejh.13714
pubmed: 34606661
Maurer K, Kim HT, Kuczmarski TM, Garrity HM, Weber A, Reynolds CG, et al. Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Adv. 2021;5:5140–9. https://doi.org/10.1182/bloodadvances.2021005139 .
doi: 10.1182/bloodadvances.2021005139
pubmed: 34581754
pmcid: 9153034
Bankova AK, Caveney J, Yao B, Ramos TL, Bogeholz J, Heydari K, et al. Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. Transpl Cell Ther. 2022;28:215.e211–e210. https://doi.org/10.1016/j.jtct.2022.01.010 .
doi: 10.1016/j.jtct.2022.01.010
Guo M, Liu J, Clark P, Ahmad S, Patel R, Varela JC, et al. Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience. Int J Hematol. 2022:1–10. https://doi.org/10.1007/s12185-022-03493-8 .
Wiercinska E, Schlipfenbacher V, Bug G, Bader P, Verbeek M, Seifried E, et al. Allogeneic transplant procurement in the times of COVID-19: Quality report from the central European cryopreservation site. J Transl Med. 2021;19:145. https://doi.org/10.1186/s12967-021-02810-9 .
doi: 10.1186/s12967-021-02810-9
pubmed: 33832504
pmcid: 8027980
Nijssen K, Westinga K, Stuut A, Janssen A, van Rhenen A, van der Wagen L, et al. Graft engineering: how long can you wait, how low can you go, and pandemic readiness. Bone Marrow Transpl. 2023: 1–3. https://doi.org/10.1038/s41409-023-01976-8 .
Facchin G, Savignano C, Battista ML, Isola M, De Martino M, Petruzzellis G, et al. Impact of Cryopreservation of Peripheral Blood Stem Cells (PBSC) in Transplantation from Matched Unrelated Donor (MUD). J Clin Med. 2022; 11. https://doi.org/10.3390/jcm11144114 .
de Witte M, Daenen LGM, van der Wagen L, van Rhenen A, Raymakers R, Westinga K, et al. Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust. Hemasphere. 2021;5:e580. https://doi.org/10.1097/HS9.0000000000000580 .
doi: 10.1097/HS9.0000000000000580
pubmed: 34095763
pmcid: 8171366
de Witte MA, Mooyaart JE, Hoogenboom JD, Chabannon C, Malard F, Ruggeri A, et al. Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party. Bone Marrow Transpl. 2023. https://doi.org/10.1038/s41409-023-01953-1 .
Purtill D, Antonenas V, Chiappini P, Tong D, O’Flaherty E, Bajel A, et al. Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic. Blood Adv. 2020;4:4147–50. https://doi.org/10.1182/bloodadvances.2020002431 .
doi: 10.1182/bloodadvances.2020002431
pubmed: 32886750
pmcid: 7479963
Wolf J, Lee J, Pearce R, Wilson M, Snowden JA, Orchard K. The impact of COVID-19 on related-donor allogeneic stem cell harvest processes: A British Society of Blood and Marrow Transplantation and Cellular Therapy survey. Br J Haematol. 2022;198:e51–53. https://doi.org/10.1111/bjh.18299 .
doi: 10.1111/bjh.18299
pubmed: 35655329
Schmidt AH, Buk D, Bernas SN, Mengling T, Neujahr E, van den Brink MRM. A DKMS (German Bone Marrow Donor Center) view on cryopreservation of unrelated donor stem cell products during the Covid-19 pandemic. Am J Hematol. 2021;96:E91–92. https://doi.org/10.1002/ajh.26081 .
doi: 10.1002/ajh.26081
pubmed: 33368593
pmcid: 7898391